GT Biopharma Inc (NASDAQ:GTBP) stock soared another 10% in the afternoon session Tuesday. The stock has been gaining momentum over the past few weeks and up over 1505 since early March.
Recently GT Biopharma announced the enrollment of Patient 10 in its GTB-3550 TriKE first-in-human Phase I/II clinical trial for the treatment of high-risk myelodysplastic syndromes (MDS) and refractory/relapsed acute myeloid leukemia (AML) forms of bone marrow cancers.
Up to 63.7% Reduction in Bone Marrow Blast Levels were observed in the first 9 patients in the study. The Patient 10 will be dosed at 100mcg/kg/day.
The company also highlighted that no Progenitor-derived or Autologous/Allogenic cell therapy was required.
“The data from the first nine patients treated with GTB-3550 indicates significant bone marrow blast level reductions in AML and MDS patients without the need for expensive progenitor-derived or autologous/allogenic cell therapies,” CEO Anthony Cataldo said.
GTBP stock has skyrocketed over 2900% from its 52-week low of $0.42.
CEO and Editor in Chief.
Living in the era of dynamic tech change Asan decided to stay tuned in changes that make any person find comfort and adapt to new devices. Furthermore, gaming became his passion for spending leisure time with his close ones. Although, he has a degree in Business Administration (majoring Finance) writing for technology and as well as finance has been one of the precious aspects of his life